via Nanyang Technological University
A team of scientists led by Nanyang Technological University, Singapore (NTU Singapore) has developed a diagnostic test that can detect the virus that causes COVID-19 even after it has gone through mutations.
Called the VaNGuard (Variant Nucleotide Guard) test, it makes use of a gene-editing tool known as CRISPR, which is used widely in scientific research to alter DNA sequences and modify gene function in human cells under lab conditions, and more recently, in diagnostic applications.
Since viruses have the ability to evolve over time, a diagnostic test robust against potential mutations is a crucial tool for tracking and fighting the pandemic. Over its course so far, thousands of variants of SARS-CoV-2, the virus that causes COVID-19, have arisen, including some that have spread widely in the United Kingdom, South Africa, and Brazil.
However, the genetic sequence variations in new strains may impede the ability of some diagnostic tests to detect the virus, said NTU Associate Professor Tan Meng How, who led the study.
In addition to its ability to detect SARS-CoV-2 even when it mutates, the VaNGuard test can be used on crude patient samples in a clinical setting without the need for RNA purification, and yields results in 30 minutes. This is a third of the time required for the gold standard polymerase chain reaction (PCR) test, which requires purification of RNA in a lab facility.
The team of scientists led by NTU hopes that the VaNGuard test can be deployed in settings where quickly confirming COVID-19 status of individuals is paramount.
Associate Professor Tan, who is from NTU’s School of Chemical and Biomedical Engineering, said: “Viruses are very smart. They can mutate, edit, or shuffle their genetic material, meaning diagnostic tests may fail to catch them. Hence, we spent considerable effort developing a robust and sensitive test that can catch the viruses even when they change their genetic sequences. In addition, frequent testing is essential for helping to break the transmission of viruses within populations, so we have developed our tests to be rapid and affordable, making them deployable in resource-poor settings.”
The findings were published in scientific journal Nature Communications on 19 March.
The research team has filed a patent for the VaNGuard test.
Moving forward, they plan to perform further experiments to further refine their diagnostic kit, obtain regulatory approval from relevant authorities, and commercialise their test in partnership with diagnostic companies.
Using a pair of “molecular scissors” to detect virus
The VaNGuard test relies on a reaction mix containing enAsCas12a, a variant of the enzyme Cas12a that acts like a pair of “molecular scissors”.
The enzyme enAsCas12a is ‘programmed’ to target specific segments of the SARS-CoV-2 genetic material and to snip them off from the rest of its viral genome. Successfully snipping off segments is how the enzyme ‘detects’ the presence of the virus. The programming is done by two different molecules known as guide RNAs, which are designed to recognise specific sites on the SARS-CoV-2 genome.
The scientists decided to use two guide RNAs that recognise sequences that are extremely similar between variants of SARS-CoV-2 and that are also unique to the virus. Each guide RNA is computationally predicted to recognise over 99.5 per cent of the thousands of SARS-CoV-2 isolates that have so far been sequenced around the world.
Assoc Prof Tan explained: “Combining two or more guide RNAs with the enzyme enAsCas12a ensures that if one of the guide RNAs fails to guide it to the correct segment of the virus because of a mutation, the other guide RNA can still ‘rescue’ this mismatch.”
So far, the made-in-NTU diagnostic platform can recognise up to two mutations within the target sites on the SARS-CoV-2 genome.
When the SARS-CoV-2 virus or one of its variants is detected in a sample, the engineered Cas12 enzyme variant enAsCas12a becomes hyper-activated and starts cutting other detectable genetic material in the sample as well, including a molecule tagged with a fluorescent dye that is added to the reaction mix.
When the molecule is cut, it starts to glow. This glow is picked up by a microplate reader, a lab instrument that can detect and quantify the light photons emitted by the molecule.
Assoc Prof Tan, who is also from the Genome Institute of Singapore at the Agency for Science, Technology and Research, Singapore (A*STAR), explained: “If the virus is present, the molecule will glow. If not, it means the virus is not present to cause the hyper-activation of the molecular scissors.”
Making the VaNGuard test easy to use
To make the test easier to use once it has been approved for roll out, the scientists integrated the test into a specially treated paper strip that looks similar to a pregnancy test.
The paper strip is dipped into a tube containing the crude nasopharyngeal sample and the reaction mix. In the presence of a SARS-CoV-2 virus or its variant, two strong bands will appear on the paper strip. In the absence of the virus, only one band will appear.
The scientists validated the VaNGuard test’s ability to detect SARS-CoV-2 variants by synthesising an RNA sample that has the same mutated sequence as a known SARS-CoV-2 variant.
They added different amounts of the synthesised sample to their test and observed two strong bands when the paper strip was dipped into each reaction mix. This indicates that the VaNGuard test is robust against mutated viral sequences. The scientists also developed a mobile phone app to facilitate the interpretation of the paper strips.
The VaNGuard test was developed by scientists from NTU’s School of Chemical and Biomedical Engineering, School of Biological Sciences, and School of Computer Science and Engineering; National University Health System; and A*STAR.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Physical therapists explain how COVID-19 impacts patients post-recovery
Parents typically expect to drive their kids to school, go to work and play with their family. However, contracting COVID-19 can derail all those plans. Now, those 40-year-olds cannot get out of bed.
- Sixers' Joel Embiid on bout with COVID-19: 'I really thought I wasn't going to make it'
Philadelphia 76ers big man Joel Embiid joined the list of NBA stars to test positive for COVID-19. But while many players have moved past the virus rather quickly, Embiid wasn't that lucky. Shortly ...
- 76ers' Joel Embiid on COVID-19 Diagnosis: 'I Thought I Wasn't Going to Make It'
"That jawn hit me hard," Embiid told reporters as he smiled. "I thought I wasn't going to make it." “I really thought I wasn’t going to make it. It was that bad.” 😳Joel Embiid's bout with COVID-19 ...
- Arizona doctor has successful double lung transplant after COVID-19 diagnosis
An Arizona doctor has a lot to be thankful for after surviving a double lung transplant. For more than 30 years, nephrologist Dr. Berne Yee has served as a kidney transplant specialist, helping to ...
- Bryan Adams announces second Covid-19 diagnosis in a month
On Thursday, the Canadian rocker shared his diagnosis on Instagram, adding that he had just landed in Italy and was going to a hospital in Milano.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Virginia will test sewage to help predict COVID-19 outbreaks
The sewage monitoring will complement other programs that monitor COVID-19 infection in the state’s communities.
- New Covid-19 variant: Antivirals hold the key as mutations surface
With Omicron appearing on the scene as the new variant of concern, experts say developing antivirals is the way forward to combat Covid in the long run. If the ever-mutating virus keeps evading the ...
- Omicron coronavirus variant has more than double the mutations of Delta, Italian lab image shows
Image created in Rome shows 43 spike protein mutations, compared to 18 for Delta. But how dangerous the new variant is remains to be seen.
- Study finds no evidence to support favipiravir use in mild or asymptomatic COVID-19 patients
Researchers conducted a Phase II randomized placebo-controlled, double-blinded trial between July 8, 2020, and March 23. 2021.
- Biden imposes travel ban from 8 African countries in response to Omicron COVID-19 variant
President Joe Biden has announced the United States is restricting travel from eight southern African countries beginning Monday due to concerns about a new variant of COVID-19, first discovered in ...